PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32243714-0	2020	A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence.	talazoparib	36-47	polo like kinase 4	Homo sapiens	15-19	
32243714-5	2020	Interestingly, talazoparib, a novel and highly potent poly-ADP-ribose polymerase 1/2 (PARP1/2) inhibitor, could increase lncRNA PLK4 expression in HepG2 cells.	talazoparib	15-26	polo like kinase 4	Homo sapiens	128-132	
32243714-6	2020	Importantly, we showed that talazoparib-induced lncRNA PLK4 could function as a tumour suppressor gene by Yes-associated protein (YAP) inactivation and induction of cellular senescence to inhibit liver cancer cell viability and growth.	talazoparib	28-39	polo like kinase 4	Homo sapiens	55-59	
32243714-7	2020	In summary, our findings reveal the molecular mechanism of talazoparib-induced anti-tumor effect, and suggest a potential clinical use of talazoparib-targeted lncRNA PLK4/YAP-dependent cellular senescence for the treatment of HCC.	talazoparib	59-70	polo like kinase 4	Homo sapiens	166-170	
32243714-7	2020	In summary, our findings reveal the molecular mechanism of talazoparib-induced anti-tumor effect, and suggest a potential clinical use of talazoparib-targeted lncRNA PLK4/YAP-dependent cellular senescence for the treatment of HCC.	talazoparib	138-149	polo like kinase 4	Homo sapiens	166-170